PRESS RELEASE published on 01/29/2024 at 22:15, 9 months 6 days ago Gedeon Richter becomes strategic investor of Formycon via equity investment Formycon AG announces strategic investment from Gedeon Richter, leading to a 9.08% equity takeover via cash capital increase of EUR 82.84 million. The investment will ensure high development pace and operational progress Pharmaceutical Industry Formycon AG Gedeon Richter Equity Investment Biosimilars
PRESS RELEASE published on 01/29/2024 at 22:10, 9 months 6 days ago EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor Formycon AG resolves on EUR 82.84 million cash capital increase by issuing 1,603,877 new shares, all subscribed by Gedeon Richter as strategic investor. Proceeds for biosimilar pipeline development. New shares to be traded on Frankfurt Stock Exchange Frankfurt Stock Exchange Formycon AG Cash Capital Increase Gedeon Richter Biosimilar Pipeline
PRESS RELEASE published on 11/10/2023 at 06:30, 11 months 25 days ago Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
PRESS RELEASE published on 10/10/2023 at 07:30, 1 year ago Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
PRESS RELEASE published on 09/29/2023 at 07:30, 1 year 1 month ago Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
PRESS RELEASE published on 08/30/2023 at 07:30, 1 year 2 months ago Formycon reports successful first half of 2023
PRESS RELEASE published on 08/29/2023 at 07:30, 1 year 2 months ago Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)
PRESS RELEASE published on 08/23/2023 at 07:30, 1 year 2 months ago Formycon hosts conference call on financial and earnings position for H1 2023
PRESS RELEASE published on 08/21/2023 at 13:42, 1 year 2 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 08/07/2023 at 08:00, 1 year 2 months ago Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar
Published on 11/05/2024 at 09:15, 24 minutes ago Troy Minerals Targets Restart of Drilling at Tsagaan Zalaa
Published on 11/05/2024 at 09:05, 34 minutes ago Omega Pacific Adds John Williamson as Independent Director
Published on 11/05/2024 at 08:00, 1 hour 39 minutes ago Touchstone Exploration Announces Execution of Licence for Rio Claro Block
Published on 11/05/2024 at 08:00, 1 hour 39 minutes ago Argo Blockchain PLC Announces October Operational Update
Published on 11/05/2024 at 03:30, 6 hours 9 minutes ago CORRECTION: Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses
Published on 11/05/2024 at 09:02, 37 minutes ago Original-Research: THE NAGA GROUP AG (von NuWays AG): Buy
Published on 11/05/2024 at 09:01, 38 minutes ago Original-Research: Marley Spoon Group SE (von NuWays AG): Buy
Published on 11/05/2024 at 09:00, 39 minutes ago Swiss Re agrees to sell iptiQ's European P&C business to Allianz Direct
Published on 11/05/2024 at 08:35, 1 hour 4 minutes ago Morocco Showcase Summit to Unveil Tourism and Investment Opportunities
Published on 11/05/2024 at 09:27, 11 minutes ago Mersen: Number of shares and voting rights as of October 31, 2024
Published on 11/05/2024 at 09:27, 11 minutes ago Mersen : nombre d'actions et de droits de vote au 31 octobre 2024
Published on 11/05/2024 at 08:30, 1 hour 9 minutes ago Cie du Bois Sauvage: Terugkoop van eigen aandelen – Week van 28/10/2024 tot 01/11/2024
Published on 11/05/2024 at 08:30, 1 hour 9 minutes ago Cie du Bois Sauvage : Rachat d’actions propres – semaine du 28/10/2024 au 01/11/2024
Published on 11/05/2024 at 08:30, 1 hour 9 minutes ago Cie du Bois Sauvage: Buy back of own shares – week from 28/10/2024 to 01/11/2024